MX365574B - 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas. - Google Patents

2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.

Info

Publication number
MX365574B
MX365574B MX2015012736A MX2015012736A MX365574B MX 365574 B MX365574 B MX 365574B MX 2015012736 A MX2015012736 A MX 2015012736A MX 2015012736 A MX2015012736 A MX 2015012736A MX 365574 B MX365574 B MX 365574B
Authority
MX
Mexico
Prior art keywords
cancer
aminopyrimidin
ones
proliferative activities
analogs exhibiting
Prior art date
Application number
MX2015012736A
Other languages
English (en)
Other versions
MX2015012736A (es
Inventor
Michael D Kaufman
Daniel L Flynn
Yu Mi Ahn
Lakshminarayana Vogeti
Timothy Malcolm Caldwell
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of MX2015012736A publication Critical patent/MX2015012736A/es
Publication of MX365574B publication Critical patent/MX365574B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

Se describen compuestos de Fórmula I (ver Fórmula) que son útiles para el tratamiento del cáncer, enfermedades autoinmunitarias y trastornos óseos metabólicos a través de la inhibición de cinas c-FMS (CSF-1R), c-KIT y/o PDGFR; estos compuestos también son útiles para el tratamiento de otras enfermedades de los mamíferos mediadas por cinasas c-FMS, c-KIT o PDGFR.
MX2015012736A 2013-03-15 2014-03-14 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas. MX365574B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792812P 2013-03-15 2013-03-15
PCT/US2014/029661 WO2014145025A2 (en) 2013-03-15 2014-03-14 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities

Publications (2)

Publication Number Publication Date
MX2015012736A MX2015012736A (es) 2016-05-31
MX365574B true MX365574B (es) 2019-06-06

Family

ID=51529950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012736A MX365574B (es) 2013-03-15 2014-03-14 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.

Country Status (18)

Country Link
US (1) US9181223B2 (es)
EP (1) EP2968286B1 (es)
JP (5) JP6165314B2 (es)
KR (4) KR102628583B1 (es)
CN (2) CN105120864B (es)
AU (5) AU2014233411B2 (es)
BR (1) BR112015022288B1 (es)
CA (1) CA2903285C (es)
DK (1) DK2968286T3 (es)
ES (1) ES2651165T3 (es)
HK (1) HK1220398A1 (es)
IL (4) IL241000B (es)
MX (1) MX365574B (es)
PH (1) PH12015502114A1 (es)
PT (1) PT2968286T (es)
RU (1) RU2015143717A (es)
SG (1) SG11201507660TA (es)
WO (1) WO2014145025A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR102628583B1 (ko) * 2013-03-15 2024-01-25 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
EP3632906B1 (en) * 2017-05-24 2023-12-13 Abbisko Therapeutics Co., Ltd. Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy
CN110461841B (zh) * 2017-06-19 2020-09-15 上海和誉生物医药科技有限公司 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用
CN110845476B (zh) * 2018-08-21 2022-11-18 上海和誉生物医药科技有限公司 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用
BR112021012812A2 (pt) * 2018-12-28 2021-12-07 Deciphera Pharmaceuticals Llc Csf1r inhibitors para uso e tratamento de câncer
MX2021013662A (es) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
RS65019B1 (sr) 2019-05-10 2024-01-31 Deciphera Pharmaceuticals Llc Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene
CN114258318A (zh) 2019-06-17 2022-03-29 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
JP2022544234A (ja) 2019-08-12 2022-10-17 デシフェラ・ファーマシューティカルズ，エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
IL293866A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Compositions of amorphous kinase inhibitors and methods of using them
IL293864A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
CN115385896A (zh) * 2021-05-24 2022-11-25 上海和誉生物医药科技有限公司 一种csf-1r抑制剂中间体或其酸式盐的制备方法
CN113880812A (zh) * 2021-11-17 2022-01-04 上海皓元生物医药科技有限公司 一种csf-ir抑制剂的制备方法
WO2023125812A1 (zh) * 2021-12-31 2023-07-06 上海海雁医药科技有限公司 取代的嘧啶酮衍生物、其药物组合物及医药上的用途
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255155A1 (en) * 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
EP2125781A2 (en) * 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
JP5444365B2 (ja) * 2008-10-29 2014-03-19 デシフェラ ファーマシューティカルズ，エルエルシー 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質
WO2014145023A1 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
KR102628583B1 (ko) * 2013-03-15 2024-01-25 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체

Also Published As

Publication number Publication date
CN105120864A (zh) 2015-12-02
AU2022204166A1 (en) 2022-06-30
AU2020205294B2 (en) 2022-03-17
DK2968286T3 (en) 2018-01-02
EP2968286B1 (en) 2017-09-13
ES2651165T3 (es) 2018-01-24
JP2021191770A (ja) 2021-12-16
CN107311981A (zh) 2017-11-03
MX2015012736A (es) 2016-05-31
IL275422A (en) 2020-08-31
WO2014145025A2 (en) 2014-09-18
KR20240013846A (ko) 2024-01-30
KR102293086B1 (ko) 2021-08-25
CN105120864B (zh) 2017-05-17
IL241000A0 (en) 2015-11-30
AU2018271293B2 (en) 2020-04-16
AU2018271293A1 (en) 2018-12-20
RU2015143717A (ru) 2017-04-28
IL289629B2 (en) 2023-08-01
JP2017193567A (ja) 2017-10-26
CA2903285C (en) 2021-05-11
KR20220070054A (ko) 2022-05-27
CA2903285A1 (en) 2014-09-18
AU2022204166B2 (en) 2024-02-15
PH12015502114B1 (en) 2016-01-25
US20140275085A1 (en) 2014-09-18
JP2023010738A (ja) 2023-01-20
BR112015022288B1 (pt) 2022-06-21
IL275422B (en) 2022-02-01
PT2968286T (pt) 2017-12-12
SG11201507660TA (en) 2015-10-29
EP2968286A2 (en) 2016-01-20
IL289629A (en) 2022-03-01
RU2015143717A3 (es) 2018-03-28
JP6165314B2 (ja) 2017-07-19
JP6936823B2 (ja) 2021-09-22
KR20150128996A (ko) 2015-11-18
JP7169412B2 (ja) 2022-11-10
KR20210107143A (ko) 2021-08-31
KR102628583B1 (ko) 2024-01-25
PH12015502114A1 (en) 2016-01-25
IL289629B1 (en) 2023-04-01
KR102399891B1 (ko) 2022-05-20
JP2016521255A (ja) 2016-07-21
AU2024202088A1 (en) 2024-05-02
WO2014145025A3 (en) 2015-01-08
IL241000B (en) 2018-07-31
IL260502B (en) 2020-07-30
AU2020205294A1 (en) 2020-08-06
AU2014233411A1 (en) 2015-09-17
AU2014233411B2 (en) 2018-09-13
US9181223B2 (en) 2015-11-10
CN107311981B (zh) 2020-05-29
HK1220398A1 (zh) 2017-05-05
EP2968286A4 (en) 2016-09-14
JP2019094350A (ja) 2019-06-20
BR112015022288A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
AU2024202088A1 (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145015A3 (en) Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
PH12015502336A1 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145029A3 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
MX364486B (es) Derivados de piridazinona-amidas.
MA40076A (fr) Inhibiteurs de syk
PH12015502615A1 (en) Chemical compounds
NZ758528A (en) Bicyclic heterocycle compounds and their uses in therapy
MX2017008442A (es) Uso de picolinamidas como fungicidas.
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
PH12016500225B1 (en) Novel quinoline-substituted compound
EA201400178A1 (ru) Лечение рака молочной железы
EA201890572A1 (ru) Биофармацевтические композиции
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX2015008877A (es) Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
GEP20186893B (en) Pyrazines modulators of gpr6
MX2017006899A (es) Sintesis de polioles polimericos en polioles insaturados, polioles polimericos y su uso.
IN2013DE02503A (es)
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина

Legal Events

Date Code Title Description
FG Grant or registration